Community-based type 2 diabetes care by lay village health workers in rural Lesotho Protocol for a cluster-randomized trial within the ComBaCaL cohort study (ComBaCaL T2D TwiC)

Author:

Gerber Felix1ORCID,Gupta Ravi2,Lejone Thabo Ishmael1,Tahirsylaj Thesar1,Lee Tristan3,Kohler Maurus1,Haldemann Maria Ines4,Räber Fabian4,Chitja Mamakhala2,Manthabiseng Molulela2,Khomolishoele Makhebe2,Mota Mota2,Bane Matumaole2,Sematle Pauline Mamorontsane2,Makabateng Retselisitsoe2,Mphunyane Madavida5,Phaaroe Sejojo5,Basler Dave Brian1,Kindler Kevin1,Seelig Eleonora1,Briel Matthias1,Chammartin Frédérique1,Labhardt Niklaus Daniel1,Amstutz Alain1

Affiliation:

1. University Hospital Basel: Universitatsspital Basel

2. SolidarMed

3. Swiss Tropical and Public Health Institute: Schweizerisches Tropen- und Public Health-Institut

4. University of Basel: Universitat Basel

5. Government of Lesotho Ministry of Health

Abstract

Abstract Background Type 2 diabetes (T2D) poses a growing public health burden, especially in low- and middle-income countries (LMICs). Task-shifting to lay village health workers (VHWs) and the use of digital clinical decision support systems (CDSS) are promising approaches to tackle the current T2D care gap in LMICs. However, evidence on the effectiveness of lay worker-led T2D care models, in which VHWs initiate and monitor drug treatment in addition to community-based screening and referral services, is lacking. Methods We are conducting a cluster-randomized trial nested within the ComBaCaL (Community-Based Chronic Disease Care Lesotho) cohort study (NCT05596773) using the trial within cohort (TwiC) design to assess the effectiveness of a VHW-led, CDSS-assisted T2D care model in rural Lesotho. Participants are non-pregnant members of the ComBaCaL cohort study with T2D. The ComBaCaL cohort study is conducted in approximately 100 villages in two rural districts in Lesotho and is managed by trained and supervised VHWs. In intervention villages, VHWs offer a community-based T2D care package including lifestyle counselling, first-line oral antidiabetic, lipid-lowering, and antiplatelet treatment guided by a tablet-based CDSS to participants who are clinically eligible, as well as treatment support to participants who prefer or clinically require facility-based T2D care. In control clusters, all participants will be referred to a health facility for T2D management. The primary endpoint is the mean glycosylated haemoglobin (HbA1c) 12 months after enrolment. Secondary endpoints include the 10-year risk for cardiovascular events estimated using the World Health Organisation risk prediction tool. Discussion The trial was launched on May 13, 2023, and has enrolled 194 participants at the date of submission (August 9, 2023). To our knowledge, the trial is the first to assess task-shifting of T2D care to VHWs at community level, including the prescription of first-line antidiabetic, lipid-lowering, and antiplatelet medication in sub-Saharan Africa, and will thus provide the missing evidence on the effectiveness of such a T2D care model in this setting. The study is operating within the established Lesotho VHW program. Similar community health worker programs which exist across sub-Saharan Africa may benefit from the findings. Trial registration The trial has been registered on clinicaltrials.gov (NCT05743387; February 24 2023).

Publisher

Research Square Platform LLC

Reference62 articles.

1. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045;Sun H;Diabetes Res Clin Pract,2022

2. The double burden of diabetes and global infection in low and middle-income countries;Dunachie S;Trans R Soc Trop Med Hyg,2019

3. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.

4. Environmental/lifestyle factors in the pathogenesis and prevention of type 2 diabetes;Kolb H;BMC Med,2017

5. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025;Lin X;Sci Rep,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3